Johnson & Johnson have announced FDA approval of ACUVUE Abiliti Overnight Therapeutic Lenses for managing myopia.
Myopia, also known as near-sightedness, is a common vision condition, but it is a chronic and progressive disease. In the UK, it is estimated that 1 in 3 people are affected by the condition. In childhood, myopia can occur between the ages of 6 – 13 and worsen in teenage years.
Experts suggest that children under 12 years old, with myopia, are most at risk of developing high myopia. The overnight lenses aim to temporarily reshape the cornea to help manage the disease, particularly in children. “We look forward to supporting parents and eye care professionals in their care of children with comprehensive resources, starting with Abiliti Overnight Therapeutic Lenses, and continuing with additional products and services to address the progression of myopia.” Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision
J&J join mark'ennovy and CooperVision who also offer contact lenses for treating Myopia.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.